AMCP Nexus 2021: What’s Promising, What’s Problematic About Prescription Digital Therapeutics

October 21, 2021

A panel discussion on prescription digital therapeutics identified them as a sweet spot for value-based agreements and collection of real-world evidence. But should they be paid for through the pharmacy benefit? And is there enough evidence available for payers and PBMs to make sound coverage and formulary decisions? For answers, stay tuned.